Glenmark, Merck to co-develop, market dermatological products for European market

By Lisa Kerner

Charlotte, N.C., July 17 - Glenmark Pharmaceuticals subsidiary Glenmark UK has signed an agreement with Merck Generics Group, a subsidiary of Merck KGaA of Darmstadt, Germany, to develop and market eight dermatological products in Europe.

The current sales value of the products is about $225 million, according to a company news release.

Glenmark will develop, manufacture and supply the products, with both companies responsible for sales and marketing.

The first product is expected to be launched in 2007 with the remaining products to be launched in 2010.

Glenmark is a Mumbai, India-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.